相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
Na Wang et al.
DIABETES METABOLIC SYNDROME AND OBESITY (2019)
Comparison of the Effect of Glycemic Control in Type 2 Diabetes Outpatients Treated With Premixed and Basal Insulin Monotherapy in China
Guangxu Liu et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial
Yingli Chen et al.
DIABETES OBESITY & METABOLISM (2018)
Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes
R. Ravi Shankar et al.
JOURNAL OF DIABETES INVESTIGATION (2017)
Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in China
Linong Ji et al.
DIABETES OBESITY & METABOLISM (2017)
Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysis
Yeong Gi Kim et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2016)
Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus
Guang Ning et al.
JOURNAL OF DIABETES (2016)
Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis
Lingyu He et al.
BMC PHARMACOLOGY & TOXICOLOGY (2016)
Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies
Michael Lehrke et al.
CLINICAL THERAPEUTICS (2014)
Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables
Li-Nong Ji et al.
BMC PUBLIC HEALTH (2013)
Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment A 1-year, randomized, double-blind, placebo-controlled study
Janet B. McGill et al.
DIABETES CARE (2013)
Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes A ≥ 52-week randomized, double-blind study
Hannele Yki-Jarvinen et al.
DIABETES CARE (2013)
Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial
Anthony H. Barnett et al.
LANCET (2013)
Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis
K. Goossen et al.
DIABETES OBESITY & METABOLISM (2012)
A review of gliptins in 2011
Andre J. Scheen
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Insulin resistance and β-cell dysfunction as therapeutic targets in type 2 diabetes
AJ Evans et al.
DIABETES OBESITY & METABOLISM (2001)
分享论文
